METEOR Studie: Retrospektive Analyse von Patienten mit fortgeschrittenem Nierenzellkarzinom bezüglich der Wirksamkeit von Cabozantinib (CABO) vs Everolimus (EVE) in Abhängigkeit vom Nephrektomiestatus

Autor: Schönheit, J, Powles, T, Tannir, N, Escudier, B, Donskov, F, Grünwald, V, Sternberg, C, Schmidinger, M, Schoffski, P, Szcylik, C, Peltola, KJ, Nosov, D, Melchiar, B, Clary, D, Scheffold, C, Motzer, R, Choueiri, T

Publikováno v: 44. gemeinsamen Tagung der Bayerischen Urologenvereinigung und der Österreichischen Gesellschaft für Urologie und Andrologie; 20180614-20180616; Rosenheim; DOC18urobay048 /20180517/

Fragestellung: Die Mehrzahl der Patienten mit fortgeschrittenem Nierenzellkarzinom (RCC) erhalten eine Nephrektomie (Nx) als kurative oder palliative Therapie. In einer retrospektiven Analyse von Patienten mit zielgerichteter Therapie erhielten solch

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d1afeab72951412bc1f5e044dbc58e4

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Safety, Efficacy, and Biological Data of T-Cell-Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial.

Autor: Pakola SA; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Peltola KJ; Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland., Clubb JHA; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd., Helsinki, Finland., Jirovec E; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Haybout L; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd., Helsinki, Finland., Kudling TV; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Alanko T; Docrates Cancer Center, Helsinki, Finland., Korpisaari R; Docrates Cancer Center, Helsinki, Finland., Juteau S; Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland., Jaakkola M; Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland., Sormunen J; Docrates Cancer Center, Helsinki, Finland., Kemppainen J; Docrates Cancer Center, Helsinki, Finland., Hemmes A; Digital Microscopy and Molecular Pathology Unit, Institute for Molecular Medicine Finland, Helsinki, Finland., Pellinen T; Digital Microscopy and Molecular Pathology Unit, Institute for Molecular Medicine Finland, Helsinki, Finland., van der Heijden M; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland., Quixabeira DCA; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd., Helsinki, Finland., Kistler C; TILT Biotherapeutics Ltd., Helsinki, Finland., Sorsa S; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd., Helsinki, Finland., Havunen R; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd., Helsinki, Finland., Santos JM; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd., Helsinki, Finland., Cervera-Carrascon V; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; TILT Biotherapeutics Ltd., Helsinki, Finland., Hemminki A; Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.; Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.; TILT Biotherapeutics Ltd., Helsinki, Finland.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Sep 03; Vol. 30 (17), pp. 3715-3725.

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.

Autor: Italiano A; Department of Medical Oncology, Institut Bergonié, 229 Cours de l'Argonne, 3300, Bordeaux, France. a.italiano@bordeaux.unicancer.fr.; University of Bordeaux, Bordeaux, France. a.italiano@bordeaux.unicancer.fr., Cassier PA; Department of Medical Oncology, Centre Leon Berard, Lyon, France., Lin CC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Alanko T; Docrates Cancer Center, Helsinki, Finland., Peltola KJ; Docrates Cancer Center, Helsinki, Finland. katriina.peltola@hus.fi.; Comprehensive Cancer Center, Helsinki University Central Hospital, Helsinki, Finland. katriina.peltola@hus.fi., Gazzah A; Department of Drug Development (DITEP), Gustave Roussy, Université Paris-Saclay, Villejuif, France., Shiah HS; Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University Hospital, Taipei, Taiwan., Calvo E; START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Hospital Madrid Norte-Sanchinarro, Madrid, Spain., Cervantes A; Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain., Roda D; Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.; CIBERONC, Instituto de Salud Carlos III, Madrid, Spain., Tosi D; Medical Oncology Department, Institut du Cancer de Montpellier, Montpellier, France., Gao B; Blacktown and Westmead Hospitals, Sydney, NSW, Australia., Millward M; Linear Clinical Research, University of Western Australia, Nedlands, WA, Australia., Warburton L; Linear Clinical Research, University of Western Australia, Nedlands, WA, Australia., Tanner M; Department of Oncology, Tampere University Hospital, Tampere, Finland., Englert S; AbbVie Deutschland, GmbH & Co KG, Ludwigshafen, Germany., Lambert S; AbbVie Inc, Redwood City, CA, USA., Parikh A; AbbVie Inc, Redwood City, CA, USA., Afar DE; AbbVie Inc, Redwood City, CA, USA., Vosganian G; AbbVie Inc, Redwood City, CA, USA., Moreno V; START Madrid-FJD, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain.

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2022 Feb; Vol. 71 (2), pp. 417-431. Date of Electronic Publication: 2021 Jul 03.